<?xml version="1.1" encoding="utf-8"?>
<article xsi:noNamespaceSchemaLocation="http://jats.nlm.nih.gov/publishing/1.1/xsd/JATS-journalpublishing1-mathml3.xsd" dtd-version="1.1" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><front><journal-meta><journal-id journal-id-type="publisher-id">JCNR</journal-id><journal-title-group><journal-title>Journal of Clinical and Nursing Research</journal-title></journal-title-group><issn>2208-3685</issn><eissn>2208-3693</eissn><publisher><publisher-name>Bio-Byword Scientific Publishing Pty. Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.26689/jcnr.v6i3.3814</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title>A Systematic Review Incorporating Meta-Analysis on the Effectiveness of Intravenous Immunoglobulin Versus Corticosteroids in the Treatment of Pediatric Myocarditis</title><url>https://artdesignp.com/journal/JCNR/6/3/10.26689/jcnr.v6i3.3814</url><author>Abdelhaleem AliAhmed Mahmoud,AbdelrahimMohamed EA</author><pub-date pub-type="publication-year"><year>2022</year></pub-date><volume>6</volume><issue>3</issue><history><date date-type="pub"><published-time>2022-04-12</published-time></date></history><abstract>Background: Concerns have been raised about&amp;nbsp;the efficacy of intravenous immunoglobulin and corticosteroids in pediatric myocarditis; however, the relationship between the risk and efficacy of these two therapies in children with myocarditis varies. Methods: A systematic review on seventeen studies was conducted in July 2020, which included 1,960 subjects at the baseline, with 788 receiving intravenous immunoglobulin and 142 receiving corticosteroids. The mean difference (MD) or odds ratio (OR) with 95% confidence intervals (CIs) was calculated to assess the prognostic role of both treatments using dichotomous and continuous methods with random or fixed-effect models. Results: The use of intravenous immunoglobulin was significantly associated with a lower mortality rate or heart transplantation in children with myocarditis (OR, 0.55; 95% CI, 0.40-0.77, p &amp;lt; 0.001) compared with the control group. However, corticosteroids were not significantly associated with the same parameters (OR, 0.72; 95% CI, 0.31-1.63, p = 0.43). The use of intravenous immunoglobulin was not significantly related to improving left ventricular ejection in children with myocarditis (OR, 2.30; 95% CI, -9.65-14.25, p = 0.71) and so were corticosteroids (MD, 5.17; 95% CI, -0.26-10.60, p = 0.06). Conclusion: The use of intravenous immunoglobulin might have an independent risk relationship with a lower mortality rate or heart transplantation and is recommended in children with myocarditis to prevent complications.</abstract><keywords/></article-meta></front><body/><back><ref-list><ref id="B1" content-type="article"><label>1</label><element-citation publication-type="journal"><p>Cooper Jr LT, 2009, Myocarditis. N Engl J Med, 360(15): 1526-1538.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B2" content-type="article"><label>2</label><element-citation publication-type="journal"><p>Rose NR, 2009, Myocarditis: Infection Versus Autoimmunity. J Clin Immunol, 29(6): 730-737.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B3" content-type="article"><label>3</label><element-citation publication-type="journal"><p>D’Ambrosio A, Patti G, Manzoli A, et al., 2001, The Fate of Acute Myocarditis Between Spontaneous Improvement and Evolution to Dilated Cardiomyopathy: A Review. Heart, 85(5): 499-504.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B4" content-type="article"><label>4</label><element-citation publication-type="journal"><p>Matsuura H, Ichida F, Saji T, et al., 2016, Clinical Features of Acute and Fulminant Myocarditis in Children–2nd Nationwide Survey by Japanese Society of Pediatric Cardiology and Cardiac Surgery. Circ J, 80(11): 2362-2368.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B5" content-type="article"><label>5</label><element-citation publication-type="journal"><p>O’Connell JB, Robinson JA, Henkin RE, et al., 1981, Immunosuppressive Therapy in Patients with Congestive Cardiomyopathy and Myocardial Uptake of Gallium-67. Circulation, 64(4): 780-786.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B6" content-type="article"><label>6</label><element-citation publication-type="journal"><p>Rose NR, 2016, Viral Myocarditis. Curr Opin Rheumatol, 28(4): 383.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B7" content-type="article"><label>7</label><element-citation publication-type="journal"><p>McNamara DM, Holubkov R, Starling RC, et al., 2001, Controlled Trial of intravenous Immune Globulin in Recent-Onset Dilated Cardiomyopathy. Circulation, 103(18): 2254-2259.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B8" content-type="article"><label>8</label><element-citation publication-type="journal"><p>Hia CPP, Yip WCL, Tai BC, et al., 2004, Immunosuppressive Therapy in Acute Myocarditis: An 18-Year Systematic Review. Arch Dis Child, 89(6): 580-584.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B9" content-type="article"><label>9</label><element-citation publication-type="journal"><p>Foerster SR, Canter CE, Cinar A, et al., 2010, Ventricular Remodeling and Survival Are More Favorable for Myocarditis Than for Idiopathic Dilated Cardiomyopathy in Childhood: An Outcomes Study from the Pediatric Cardiomyopathy Registry. Circ Heart Fail, 3(6): 689-697.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B10" content-type="article"><label>10</label><element-citation publication-type="journal"><p>Drucker NA, Colan SD, Lewis, A.B., et al., 1994, Gamma-Globulin Treatment of Acute Myocarditis in the Pediatric Population. Circulation, 89(1): 252-257.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B11" content-type="article"><label>11</label><element-citation publication-type="journal"><p>Prasad AN, Chaudhary S, 2014, Intravenous Immunoglobulin in Children with Acute Myocarditis and/or Early Dilated Cardiomyopathy. Indian Pediatr, 51(7): 583-584.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B12" content-type="article"><label>12</label><element-citation publication-type="journal"><p>Heidendael JF, Den Boer SL, Wildenbeest JG, et al., 2018, Intravenous Immunoglobulins in Children with New Onset Dilated Cardiomyopathy. Cardiol Young, 28(1): 46-54.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B13" content-type="article"><label>13</label><element-citation publication-type="journal"><p>Bhatt GC, Sankar J, Kushwaha K, 2012, Use of Intravenous Immunoglobulin Compared with Standard Therapy Is Associated with Improved Clinical Outcomes in Children with Acute Encephalitis Syndrome Complicated by Myocarditis. Pediatr Cardiol, 33(8): 1370-1376.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B14" content-type="article"><label>14</label><element-citation publication-type="journal"><p>Yen MH, Huang YC, Chen MC, et al., 2015, Effect of Intravenous Immunoglobulin for Neonates with Severe Enteroviral Infections with Emphasis on the Timing of Administration. J Clin Virol, 64: 92-96.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B15" content-type="article"><label>15</label><element-citation publication-type="journal"><p>Haque A, Bhatti S, Siddiqui FJ, 2009, Intravenous Immune Globulin for Severe Acute Myocarditis in Children. Indian Pediatr, 46(9): 801-811.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B16" content-type="article"><label>16</label><element-citation publication-type="journal"><p>Stroup DF, Berlin JA, Morton SC, et al., 2000, Meta-Analysis of Observational Studies in Epidemiology: A Proposal for Reporting. JAMA, 283(15): 2008-2012.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B17" content-type="article"><label>17</label><element-citation publication-type="journal"><p>Moher D, Liberati A, Tetzlaff J, et al., 2009, Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med, 6(7): e1000097.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B18" content-type="article"><label>18</label><element-citation publication-type="journal"><p>Gupta A, Das A, Majumder K, et al., 2018, Obesity Is Absolutely Associated with Increased Risk of Hepatocellular Cancer–related Mortality. Am J Clin Oncol, 41(9): 874-881.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B19" content-type="article"><label>19</label><element-citation publication-type="journal"><p>O’Neil ME, Cheney TP, Hsu FC, 2020, Exploration of Risk of Bias Elements and Assessment Methods, in Pharmacologic and Nonpharmacologic Treatments for Posttraumatic Stress Disorder: An Update of the PTSD-Repository Evidence Base, Agency for Healthcare Research and Quality, US.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B20" content-type="article"><label>20</label><element-citation publication-type="journal"><p>Higgins JP, Thompson SG, Deeks JJ, et al., 2003, Measuring Inconsistency in Meta-Analyses. BMJ, 327(7414): 557-560.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B21" content-type="article"><label>21</label><element-citation publication-type="journal"><p>Klugman D, Berger JT, Sable CA, et al., 2010, Pediatric Patients Hospitalized with Myocarditis: A Multi-Institutional Analysis. Pediatr Cardiol, 31(2): 222-228.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B22" content-type="article"><label>22</label><element-citation publication-type="journal"><p>Kim HJ, Yoo G-H, Kil HR, 2010, Clinical Outcome of Acute Myocarditis in Children According to Treatment Modalities. Korean J Pediatr, 53(7): 745.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B23" content-type="article"><label>23</label><element-citation publication-type="journal"><p>Butts RJ, Boyle GJ, Deshpande SR, et al., 2017, Characteristics of Clinically Diagnosed Pediatric Myocarditis in a Contemporary Multi-Center Cohort. Pediatr Cardiol, 38(6): 1175-1182.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B24" content-type="article"><label>24</label><element-citation publication-type="journal"><p>Ghelani SJ, Spaeder MC, Pastor W, et al., 2012, Demographics, Trends, and Outcomes in Pediatric Acute Myocarditis in the United States, 2006 to 2011. Circ Cardiovasc Qual Outcomes, 5(5): 622-627.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B25" content-type="article"><label>25</label><element-citation publication-type="journal"><p>Kishimoto C, Shioji K, Hashimoto T, et al., 2014, Therapy with Immunoglobulin in Patients with Acute Myocarditis and Cardiomyopathy: Analysis of Leukocyte Balance. Heart Vessels, 29(3): 336-342.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B26" content-type="article"><label>26</label><element-citation publication-type="journal"><p>Atiq M, Hoda M, Aslam N, 2014, Effect of Intravenous Gamma Globulin on Short- and Mid-Term Clinical Outcome in Acute Viral Myocarditis in Children. World J Cardiovasc, 4(2): 42803.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B27" content-type="article"><label>27</label><element-citation publication-type="journal"><p>English RF, Janosky JE, Ettedgui JA, et al., 2004, Outcomes for Children with Acute Myocarditis. Cardiol Young, 14(5): 488.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B28" content-type="article"><label>28</label><element-citation publication-type="journal"><p>Camargo PR, Snitcowsky R, Da Luz PL, et al., 1995, Favorable Effects of Immunosuppressive Therapy in Children with Dilated Cardiomyopathy and Active Myocarditis. Pediatr Cardiol, 16(2): 61-68.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B29" content-type="article"><label>29</label><element-citation publication-type="journal"><p>Aziz KU, Patel N, Sadullah T, et al., 2010, Acute Viral Myocarditis: Role of Immunosuppression: A Prospective Randomized Study. Cardiol Young, 20(5): 509-515.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B30" content-type="article"><label>30</label><element-citation publication-type="journal"><p>Heart Failure Society of America, 2010, Section 16: Myocarditis: Current Treatment. J Card Fail, 16(6): e176-e179.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B31" content-type="article"><label>31</label><element-citation publication-type="journal"><p>Pollack A, Kontorovich AR, Fuster V, et al., 2015, Viral Myocarditis – Diagnosis, Treatment Options, and Current Controversies. Nat Rev Cardiol, 12(11): 670-680.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B32" content-type="article"><label>32</label><element-citation publication-type="journal"><p>Wojnicz R, Nowalany-Kozielska E, Wojciechowska C, et al., 2001, Randomized, Placebo-Controlled Study for Immunosuppressive Treatment of Inflammatory Dilated Cardiomyopathy: Two-Year Follow-Up Results. Circulation, 104(1): 39-45.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B33" content-type="article"><label>33</label><element-citation publication-type="journal"><p>Frustaci A, Russo MA, Chimenti C, 2009, Randomized Study on the Efficacy of Immunosuppressive Therapy in Patients with Virus-Negative Inflammatory Cardiomyopathy: The TIMIC Study. Eur Heart J, 30(16): 1995-2002.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B34" content-type="article"><label>34</label><element-citation publication-type="journal"><p>Lu C, Qin F, Yan Y, et al., 2016, Immunosuppressive Treatment for Myocarditis: A Meta-Analysis of Randomized Controlled Trials. J Cardiovasc Med, 17(8): 631-637.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B35" content-type="article"><label>35</label><element-citation publication-type="journal"><p>Maisch B, Alter P, 2018, Treatment Options in Myocarditis and Inflammatory Cardiomyopathy. Herz, 43(5): 423-430.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B36" content-type="article"><label>36</label><element-citation publication-type="journal"><p>Robinson J, Hartling L, Vandermeer B, et al., 2020, Intravenous Immunoglobulin for Presumed Viral Myocarditis in Children and Adults. Cochrane Database Syst Rev, 19(8): CD004370.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B37" content-type="article"><label>37</label><element-citation publication-type="journal"><p>Amabile N, Fraisse A, Bouvenot J, et al., 2006, Outcome of Acute Fulminant Myocarditis in Children. Heart, 92(9): 1269-1273.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B38" content-type="article"><label>38</label><element-citation publication-type="journal"><p>Liu C, Chen J, Liu K, 2005, Immunosuppressive Treatment for Inflammatory Cardiomyopathy. Int Heart J, 46(1): 113-122.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B39" content-type="article"><label>39</label><element-citation publication-type="journal"><p>Madney YM, Fathy M, Elberry AA, et al., 2019, Aerosol Delivery Through an Adult High-Flow Nasal Cannula Circuit Using Low-Flow Oxygen. Respir Care, 64(4): 453-461.</p><pub-id pub-id-type="doi"/></element-citation></ref></ref-list></back></article>
